CHAIR
:
SPEAKER
(S):
DR Isaac Kohane, Lawrence J. Henderson Professor of Pediatrics and HST, Harvard Medical School MA, United States
Mara Aspinall, President, Genzyme Genetics
Paul Keckley, PhD, Executive Director, Vanderbilt University Center for Evidence-based Medicine
Stephen Eck, MD, PhD, Vice President, Pfizer Global R&D Molecular Profiling
Description
What if science could substantially improve human health through personalized medicine and targeted therapies--and society in the aggregate could afford it, but the current health economic system could not pay for it? We will explore how the health economy may or may not change and try to anticipate possible strategies for life sciences companies as change unfolds.
Objectives:
Understand the current and emerging models of targeted therapies.
Anticipate the potential economic challenges to bringing the science to patients.
Explore strategies that could help overcome these challenges.